Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series
Oncology Research and Treatment · 2024
DOI: 10.1159/000540613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Giuseppe Bianchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: 3rd Orthopedic and Traumatologic Clinic prevalently Oncologic IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Hauptthemen laut MEDLINE: Sarcoma, Ewing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Introduction
Extraskeletal Ewing sarcoma (EEwS) is a rare malignant tumor, and current international recommendations indicate systemic and local treatment like bone Ewing sarcoma (BEwS); to the best of our knowledge, very few studies tried to explore the clinical and genetic characteristics of this tumor, and the most appropriate treatment strategy remains uncertain.
Methods
We reviewed 35 EEwS cases enrolled at Rizzoli Orthopedic Institute in Bologna, Italy, between 1988–2022. We performed RNA sequencing in 18 Ewing sarcoma cases, including 12 BEwSs and 6 EEwSs. We analyzed overall survival (OS), local relapse-free survival (LRFS), and metastasis-free survival (MFS) and the risk factors associated to survival.
Results
Unsupervised hierarchical clustering showed no differences in the transcriptional profile between EEwS and BEwS. Five-year OS was 67% (95% confidence interval [CI]: 47–80), 5-year LRFS was 61% (95% CI: 43–75), and 5-year MFS was 55% (95% CI: 38–70). Recurrent tumors, larger than 8 cm, and elevated lactate dehydrogenase (LDH) serum value resulted to be negative prognostic factors.
Conclusions
The finding/detection of a genetic profile that is indistinguishable between EEwS and BEwS confirms the view that the two subgroups belong to the same tumor entity and supports the use of a single therapeutic approach for Ewing sarcoma, regardless of the site of origin. Statistical evaluation showed that size bigger than 8 cm, elevated LDH, and recurrent tumors had a worse prognosis, suggesting a risk-stratification method for identifying patients for specific therapy treatment. However, larger, multicenter, prospective trials are called for to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 3rd Orthopedic and Traumatologic Clinic prevalently Oncologic IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
- Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
- Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
- Pathology Department, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
- Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
Zitieren
APA
Bianchi, G., Laginestra, M. A., Simonetti, E., Ibrahim, T., Macrì, F., Ostetto, F., Tuzzato, G., Paioli, A., Gambarotti, M., Cocchi, S., Donati, D. M., Scotlandi, K., & Laranga, R. (2024). Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series. Oncology Research and Treatment. https://doi.org/10.1159/000540613
Vancouver
Bianchi G, Laginestra MA, Simonetti E, Ibrahim T, Macrì F, Ostetto F, et al. Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series. Oncology Research and Treatment. 2024. doi:10.1159/000540613
BibTeX
@article{Bianchi2024,
author = {Bianchi, Giuseppe and Laginestra, Maria Antonella and Simonetti, Elisa and Ibrahim, Toni and Macrì, Fabiana and Ostetto, Federico and Tuzzato, Gianmarco and Paioli, Anna and Gambarotti, Marco and Cocchi, Stefania and Donati, Davide Maria and Scotlandi, Katia and Laranga, Roberta},
title = {Extraskeletal Ewing Sarcoma of the Extremities and Trunk: A Retrospective Analysis of a Mono-Institutional Series},
journal = {Oncology Research and Treatment},
year = {2024},
doi = {10.1159/000540613}
}
EUVIMED